Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Better Collective bets on Mindway AI
Founded out of Aarhus University in 2004, Mindway AI builds artificial intelligence-driven tools to prevent problem gambling.
NexImmune elects to launch initial public offering
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Vor Biopharma goes for $150m in IPO
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Immunocore plots course to $100m IPO
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
A1 Group acquires Invenium
The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.
Ampacimon procures Diael in acquisition deal
The insulation breakage measuring device producer is joining Ampacimon having launched out of Polytechnic University of Madrid over ten years ago.
Biohaven brings Kleo into the fold
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Other News

Sana to seek $150m in IPO
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
908 Devices inflates IPO to $150m
The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
Sonovia sounds out stock market
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
WealthNavi navigates its way through $173m IPO
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
AbCellera amplifies IPO to $556m
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
GoDaddy makes $365m Poynt acquisition
Stanford-StartX Fund is set to exit payment processing technology provider Poynt in an acquisition sized at up to $365m.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg